BUSINESS
Bodal Chemicals: Diversification towards benzene chemistry – a structural shift
Import for select benzene-based chemicals is on an uptrend and hence offers a good import substitution opportunity for Bodal Chemicals
BUSINESS
Navin Fluorine: Can it continue to outperform with an eye on the next leg of growth?
Navin Fluorine’s recent capex announcements add to conviction that it's increasingly evaluating other complex applications of fluorine chemistry and looks well focused to diversify into higher margin products
MARKETS
Fed: Vaccine rollout strengthens medium-term recovery
Although news flow about vaccine approval and distribution is positive, the continuing pandemic and the fragility in the economy make the next 4-6 months quite crucial
BUSINESS
Rain Industries: Is the worst behind?
Overall growth environment is fragile but we estimate that the near-term stress in the demand environment is already priced in Rain's valuations
BUSINESS
Colgate Palmolive: Raw material tailwind adds to shine
Colgate’s strong brand recall among consumers, new launches and higher brand investment should help it post better market share going forward
BUSINESS
Britannia — Look beyond near-term haze
As for the capex plan of over Rs 700 crore, Britannia prioritises for newer plants in Tamil Nadu and UP, followed by Bihar
BUSINESS
Hindustan Unilever: Can the elephant dance like a Pro?
Going forward, challenges cited by HUL are uncertain growth outlook for urban areas, inflationary pressure and subdued prospects for winter
BUSINESS
Phillips Carbon: A commodity chemical play at attractive valuation
In the medium term, Phillips Carbon Black's growth is likely to be a function of volume growth
BUSINESS
Bhansali Engineering: Proxy to auto recovery, but can it re-rate from here?
While Bhansali Engineering's current trading multiples are at a discount to sector and its own historical highs, we believe there is limited scope for re-rating from here
BUSINESS
This food colour company’s business model makeover and capex plans need a close watch
In the near term, an improving product mix, lower share of trading business and backward integration are expected to improve earnings for Vidhi Specialty
BUSINESS
Cadila: a formidable play in Covid times and beyond
Cadila is not only a credible Indian pharma striving for a Covid solution, but on a longer time scale is an interesting watch in the large-cap space witnessing a significant transformation in product portfolio.
BUSINESS
What’s in store for Shivalik Rasayan?
What goes in favour of Shivalik Rasayan is a strong promoter who has been instrumental in reviving legacy businesses
BUSINESS
Chemcon IPO: A strong import substitute play, but does it merit investors’ attention?
With respect to the industry’s historical valuation multiple range, Chemcon’s multiples are at the higher end.
BUSINESS
Perrigo’s pain is a windfall for Cipla, Lupin
This recall of Albuterol product by Perrigo has an immediate positive impact on the sales of similar respiratory products by competitors such as Cipla and Lupin
BUSINESS
Post weak operational show for this Vitamin D API maker, what’s in store for investors?
Fermenta Biotech is looking to capitalise on the API sourcing shift to India by focusing on product extensions and capacity expansion
BUSINESS
Fed: Low for longer extends through 2023
Markets react to delta/change in events, numbers and narrative. Prospects of additional fiscal stimulus, geopolitical risks and uncertainty with respect to US elections will get more and more investor attention
BUSINESS
Aurobindo Pharma: Shot in the arm for Covid vaccine development programme
Vaccine capacity creation puts Aurobindo in the league of Serum Institute of India and Cadila in the race for a Covid drug
BUSINESS
Is Shivalik Rasayan’s valuation fair after the recent run-up?
Investors should acknowledge that traction in oncology value chain – APIs and formulation – could be a game changer, not only in terms of top line growth but also margin profile
BUSINESS
Hikal: Focus on operational risk management adds to conviction
Any protectionist measure from the government, given the recent trend towards ant-dumping duty and Make in India theme could disproportionately benefit the Hikal
BUSINESS
Fed: There are things like the Virus which money can’t buy, for everything else it’s the US FED
This however doesn’t take away the risks. The virus is the central risk. It can jeopardise and delay the economic recovery, leading to more financial instability
BUSINESS
Nestle: Strong cash flows help it combat headwinds
Investors should take comfort from the fact that Nestle has continued to focus on innovation and has launched 71 new products since 2016
BUSINESS
Tech Mahindra – Better numbers may support a trading rally
The geo-political tug of war is a crucial factor for the 5G rollout and hence, Tech Mahindra sees this opportunity coming in phases. We see the play panning out from H2 FY22 onwards
BUSINESS
Pharma: Trump’s executive orders may possibly provide better market access opportunities
Indian drugmakers such as Cipla, Cadila, Lupin, Dr Reddy’s, Sun Pharma and a few small-sized pharma companies such as Laurus Labs may benefit from a likely revamp of US medicare
BUSINESS
Himadri Speciality: Outcome of carbon black anti-dumping review a key event to watch
Himadri Speciality's valuations are still ahead of peers in the carbon space but justified due to diversified and vertically integrated portfolio
